Cargando…

Effects of Renal Impairment on the Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets

BACKGROUND: An extended-release formulation of amantadine (Osmolex ER™, Osmotica Pharmaceutical US LLC) was approved in February 2018 to treat Parkinson’s disease and drug-induced extrapyramidal reactions in adults. OBJECTIVES: To determine the pharmacokinetic profile of extended-release amantadine...

Descripción completa

Detalles Bibliográficos
Autores principales:	deVries, Tina, Dentiste, Angela, Di Lea, Clifford, Pichette, Vincent, Jacobs, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6669187/ https://www.ncbi.nlm.nih.gov/pubmed/31342404 http://dx.doi.org/10.1007/s40263-019-00651-1

Ejemplares similares

Bioavailability and Pharmacokinetics of Once-Daily Amantadine Extended-Release Tablets in Healthy Volunteers: Results from Three Randomized, Crossover, Open-Label, Phase 1 Studies
por: deVries, Tina, et al.
Publicado: (2019)

Pharmacokinetics of ADS-5102 (Amantadine) Extended Release Capsules Administered Once Daily at Bedtime for the Treatment of Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2018)

Pharmacokinetics of Once‐Daily Extended‐Release Tacrolimus Tablets Versus Twice‐Daily Capsules in De Novo Liver Transplant
por: DuBay, Derek A., et al.
Publicado: (2019)

Formulation and Evaluation of Once Daily Minocycline Hydrochloride Extended Release Matrix Tablets
por: Keny, R. V., et al.
Publicado: (2009)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: randomized, controlled clinical trial
por: Okuda, Darin T, et al.
Publicado: (2022)

Arbaclofen extended-release tablets for spasticity in multiple sclerosis: open-label extension study
por: Okuda, Darin T, et al.
Publicado: (2023)

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food
por: Lamba, Manisha, et al.
Publicado: (2016)

Evaluation of Flexible Tacrolimus Drug Concentration Monitoring Approach in Patients Receiving Extended‐Release Once‐Daily Tacrolimus Tablets
por: Philosophe, Benjamin, et al.
Publicado: (2018)

Twice-Daily versus Once-Daily Pramipexole Extended Release Dosage Regimens in Parkinson's Disease
por: Yun, Ji Young, et al.
Publicado: (2017)

Effects of Gocovri (Amantadine) Extended-Release Capsules on Motor Aspects of Experiences of Daily Living in People with Parkinson’s Disease and Dyskinesia
por: Hauser, Robert A., et al.
Publicado: (2021)

Bioavailability of oxycodone after administration of a new prolonged-release once-daily tablet formulation in healthy subjects, in comparison to an established twice-daily tablet
por: Scheidel, Bernhard, et al.
Publicado: (2017)

Maintaining remission in ulcerative colitis – role of once daily extended-release mesalamine
por: Oliveira, Lilliana, et al.
Publicado: (2011)

The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain
por: Knezevic, Nebojsa Nick, et al.
Publicado: (2019)

Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2016)

Oral Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users
por: Harris, Stephen C., et al.
Publicado: (2017)

HIV virologic response better with single-tablet once daily regimens compared to multiple-tablet daily regimens
por: Kapadia, Shashi N, et al.
Publicado: (2018)

Repeat-dose steady-state pharmacokinetic evaluation of once-daily hydromorphone extended-release (OROS(®) hydromorphone ER) in patients with chronic pain
por: Vandenbossche, Joris, et al.
Publicado: (2012)

Model‐Informed Development and Registration of a Once‐Daily Regimen of Extended‐Release Tofacitinib
por: Lamba, M, et al.
Publicado: (2017)

Amantadine extended release for levodopa‐induced dyskinesia in Parkinson's disease (EASED Study)
por: Pahwa, Rajesh, et al.
Publicado: (2015)

Amantadine extended-release capsules for levodopa-induced dyskinesia in patients with Parkinson’s disease
por: Sharma, Vibhash D, et al.
Publicado: (2018)

Amantadine delayed release/extended release capsules significantly reduce OFF time in Parkinson’s disease
por: Hauser, Robert A., et al.
Publicado: (2022)

A prospective cohort conversion study of twice-daily to once-daily extended-release tacrolimus: role of ethnicity
por: Glick, Lauren, et al.
Publicado: (2014)

Effectiveness and Safety of Once-Daily Extended-Release Hydrocodone in Individuals Previously Receiving Immediate-Release Oxycodone for Chronic Pain
por: Pergolizzi, Joseph, et al.
Publicado: (2018)

Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus
por: Hawi, Amale, et al.
Publicado: (2015)

Tolerability and safety of gastroretentive once-daily gabapentin tablets for the treatment of postherpetic neuralgia
por: Irving, Gordon A, et al.
Publicado: (2012)

Achieving a physiological cortisol profile with once-daily dual-release hydrocortisone: a pharmacokinetic study
por: Johannsson, Gudmundur, et al.
Publicado: (2016)

Cost-effectiveness of the once-daily efavirenz/emtricitabine/tenofovir tablet compared with the once-daily elvitegravir/cobicistat/emtricitabine/tenofovir tablet as first-line antiretroviral therapy in HIV-infected adults in the US
por: Juday, Timothy, et al.
Publicado: (2013)

Conversion From Twice-Daily Tacrolimus to Once-Daily Extended Release Tacrolimus (LCPT): The Phase III Randomized MELT Trial
por: Bunnapradist, S, et al.
Publicado: (2013)

Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Clinical utility and consumer considerations for the use of once-daily nevirapine extended release for HIV infection treatment
por: Yone, Eric W Pefura, et al.
Publicado: (2012)

The pharmacokinetics of once-daily dosing with gentamicin in women with postpartum endometritis.
por: Sunyecz, J A, et al.
Publicado: (1998)

Among once-daily regimens, single tablet regimens (STRs) are associated with better adherence
por: Murri, R, et al.
Publicado: (2012)

An observational study of once-daily modified-release methylphenidate in ADHD: effectiveness on symptoms and impairment, and safety
por: Döpfner, Manfred, et al.
Publicado: (2011)

Correction: Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus
por: Levy, Juliana, et al.
Publicado: (2010)

Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder
por: Endicott, Jean, et al.
Publicado: (2012)

Effects of Gocovri (Amantadine) Extended Release Capsules on Non-Motor Symptoms in Patients with Parkinson’s Disease and Dyskinesia
por: Mehta, Shyamal H., et al.
Publicado: (2021)

Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets
por: Kim, Ju-Young, et al.
Publicado: (2015)

Real-World Study of Once-Daily, Extended-Release Tacrolimus Versus Twice-Daily, Immediate-Release Tacrolimus in Kidney Transplantation: Clinical Outcomes and Healthcare Resource Utilization
por: Ho, Bing, et al.
Publicado: (2019)

Additive Manufacturing of an Extended-Release Tablet of Tacrolimus
por: Abdollahi, Azin, et al.
Publicado: (2023)

Antituberculosis Macozinone Extended-Release Tablets To Enhance Bioavailability: a Pilot Pharmacokinetic Study in Beagle Dogs
por: Koryakova, Angela, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_62bshb278j2i76g0se9tiqqset